SCHEMBL201440

SCHEMBL201440

CCCCCCOc1cc(F)cc(C(N)=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 0.59
TP53 P04637 2/20 0.48
TSHR P16473 1/20 0.48
SMPD1 P17405 3/20 0.47
PLA2G4B P0C869 2/20 0.47
BLM P54132 1/20 0.46
RARB P10826 3/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.44
NR1I2 O75469 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADRA2A P08913 1/20 0.44
OPRK1 P41145 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5086980 0.89 PLA2G2A (0.73) PLA2G2ATP53TSHRSMPD1PLA2G4B
SCHEMBL11695455 0.89 PLA2G2A (0.73) PLA2G2ATP53TSHRSMPD1PLA2G4B
SCHEMBL14763514 0.89 PLA2G2A (0.73) PLA2G2ATP53TSHRSMPD1PLA2G4B
Hydrochloric Acid SCHEMBL5005668 0.88 PLA2G2A (0.71) PLA2G2ATP53TSHRSMPD1PLA2G4B
SCHEMBL9168399 0.84 PLA2G2A (0.60) PLA2G2ATP53TSHRSMPD1PLA2G4B
SCHEMBL203212 0.84 PLA2G2A (0.60) PLA2G2ATP53TSHRSMPD1PLA2G4B
SCHEMBL15977059 0.82 PLA2G2A (0.57) PLA2G2ATP53TSHRPLA2G4BNPC1
SCHEMBL17414620 0.82 PLA2G2A (0.62) PLA2G2ATP53TSHRPLA2G4BBLM
SCHEMBL17284927 0.81 PLA2G2A (0.53) PLA2G2ATP53TSHRPLA2G4BBLM
SCHEMBL8646110 0.81 PLA2G2A (0.53) PLA2G2ATP53TSHRPLA2G4BBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102008459-B Antibacterial agents BIOTA SCIENT MAN 2013-05-29 CN claimed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
CN-102008459-B Antibacterial agents BIOTA SCIENT MAN 2013-05-29 CN disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
CN-101404989-B Antibacterial agent PROLYSIS LTD 2011-10-05 CN disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
CN-102008459-A Antibacterial agents PROLYSIS LTD 2011-04-13 CN disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 PLA2G2A 4676/4885TP53 4103/4885TSHR 1283/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 PLA2G2A 4386/4885TP53 4004/4885TSHR 844/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 PLA2G2A 4676/4885TP53 4103/4885TSHR 1283/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 PLA2G2A 4676/4885TP53 4103/4885TSHR 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.